Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | 14-Jul-22 |
| Call for patient/clinician input closed | 02-Sep-22 |
| Clarification: - Patient input submission received from Diabetes Canada | |
| Submission received | 12-Aug-22 |
| Submission accepted | |
| Clarification: - Submission was not accepted for review on 26 Aug 2022 | |
| Call for patient/clinician input open | 07-Jul-22 |
|---|---|
| Call for patient/clinician input closed | 26-Aug-22 |
| Clarification: - Patient input submission received from the Canadian Cancer Society | |
| Call for industry input open | 07-Jul-22 |
| Call for industry input closed | 26-Aug-22 |
| Review initiated | 06-Sep-22 |
| Expert committee meeting (initial) | 29-Jun-23 |
| Draft recommendation posted for stakeholder feedback | 20-Jul-23 |
| End of feedback period | 03-Aug-23 |
| Final recommendation posted | 08-Sep-23 |
| Canada's Drug Agency review report(s) posted | 08-Sep-23 |
Key Milestones2 |
|
|---|---|
| Call for patient/clinician input open | July 04, 2022 |
| Call for patient/clinician input closed | August 26, 2022 |
| Clarification:
- Patient input submission received from Osteoporosis Canada |
|
| Submission received | August 02, 2022 |
| Submission accepted | August 19, 2022 |
| Review initiated | August 22, 2022 |
| Clarification:
Voluntarily withdrawn by the sponsor on 04 Nov 2022 |
|
| Call for patient/clinician input open | July 05, 2022 |
|---|---|
| Call for patient/clinician input closed | August 26, 2022 |
| Clarification: - Patient input submission received from the Canadian Breast Cancer Network and Rethink Breast Cancer | |
| Submission received | August 03, 2022 |
| Submission accepted | August 17, 2022 |
| Review initiated | August 18, 2022 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | November 17, 2022 |
| Deadline for sponsors comments | November 28, 2022 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | December 22, 2022 |
| Expert committee meeting (initial) | January 11, 2023 |
| Draft recommendation issued to sponsor | January 24, 2023 |
| Draft recommendation posted for stakeholder feedback | February 02, 2023 |
| End of feedback period | February 16, 2023 |
| Final recommendation issued to sponsor and drug plans | March 01, 2023 |
| Final recommendation posted | March 20, 2023 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | March 15, 2023 |
| Canada's Drug Agency review report(s) posted | May 09, 2023 |
| Call for patient/clinician input open | 30-Jun-22 |
|---|---|
| Call for patient/clinician input closed | 22-Aug-22 |
| Clarification: - Patient input submission received from CARP (Canadian Association of Retired Persons), and The Kidney Foundation of Canada | |
| Call for industry input open | 30-Jun-22 |
| Call for industry input closed | 22-Aug-22 |
| Clarification: - Patient input submission received from Canadian Association of Retired Persons and The Kidney Foundation of Canada | |
| Expert committee meeting (initial) | 29-Jun-23 |
| Draft recommendation posted for stakeholder feedback | 20-Jul-23 |
| End of feedback period | 03-Aug-23 |
| Final recommendation posted | 23-Aug-23 |
| Canada's Drug Agency review report(s) posted | 23-Aug-23 |
See Pharmaceutical Reviews Update ― Issue 32 for important news and information regarding the Canada's Drug Agency drug review programs. Highlights from this issue include:
See Pharmaceutical Reviews Update ― Issue 30 for important news and information regarding the Canada's Drug Agency drug review programs. Highlights from this issue include:
Review Type: Rapid
Provisional Funding Algorithm |
|
|---|---|
| Draft Report Posted: | October 20, 2022 |
| Stakeholder Feedback Deadline: | October 27, 2022 |
| Final Report Posted: | December 01, 2022 |
Review Type: Rapid
Provisional Funding Algorithm |
|
|---|---|
|
Draft Report Posted: |
September 15, 2022 |
|
Stakeholder Feedback Deadline: |
September 22, 2022 |
|
Final Report Posted: |
November 15, 2022 |
Review Type: Rapid